Bain Capital Life Sciences Investors, LLC Savara Inc Put Options Transaction History
Bain Capital Life Sciences Investors, LLC
- $662 Million
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding SVRA
# of Institutions
122Shares Held
121MCall Options Held
123KPut Options Held
14.7K-
Nea Management Company, LLC Timonium, MD24.5MShares$112 Million8.55% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA10MShares$45.7 Million5.24% of portfolio
-
Jennison Associates LLC8.84MShares$40.4 Million0.03% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.29MShares$37.9 Million0.08% of portfolio
-
Black Rock Inc. New York, NY7.24MShares$33.1 Million0.0% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $521M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.